Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials

Nonalcoholic fatty liver disease (NAFLD) has a high prevalence worldwide, but there are no medications approved for treatment. Gut microbiota would be a novel and promising therapeutic target based on the concept of the gut–liver axis in liver disease. We reviewed randomized controlled trials on gut...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Ting-Rui, Yang, Wen-Juan, Tan, Qing-Hua, Bai, Shuai, Zhong, Huang, Tai, Yang, Tong, Huan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884806/
https://www.ncbi.nlm.nih.gov/pubmed/36726574
http://dx.doi.org/10.3389/fmicb.2022.1004911
_version_ 1784879792807477248
author Han, Ting-Rui
Yang, Wen-Juan
Tan, Qing-Hua
Bai, Shuai
Zhong, Huang
Tai, Yang
Tong, Huan
author_facet Han, Ting-Rui
Yang, Wen-Juan
Tan, Qing-Hua
Bai, Shuai
Zhong, Huang
Tai, Yang
Tong, Huan
author_sort Han, Ting-Rui
collection PubMed
description Nonalcoholic fatty liver disease (NAFLD) has a high prevalence worldwide, but there are no medications approved for treatment. Gut microbiota would be a novel and promising therapeutic target based on the concept of the gut–liver axis in liver disease. We reviewed randomized controlled trials on gut microbiota therapy in NAFLD in this study to evaluate its efficacy and plausibility in NAFLD.
format Online
Article
Text
id pubmed-9884806
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98848062023-01-31 Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials Han, Ting-Rui Yang, Wen-Juan Tan, Qing-Hua Bai, Shuai Zhong, Huang Tai, Yang Tong, Huan Front Microbiol Microbiology Nonalcoholic fatty liver disease (NAFLD) has a high prevalence worldwide, but there are no medications approved for treatment. Gut microbiota would be a novel and promising therapeutic target based on the concept of the gut–liver axis in liver disease. We reviewed randomized controlled trials on gut microbiota therapy in NAFLD in this study to evaluate its efficacy and plausibility in NAFLD. Frontiers Media S.A. 2023-01-16 /pmc/articles/PMC9884806/ /pubmed/36726574 http://dx.doi.org/10.3389/fmicb.2022.1004911 Text en Copyright © 2023 Han, Yang, Tan, Bai, Zhong, Tai and Tong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Han, Ting-Rui
Yang, Wen-Juan
Tan, Qing-Hua
Bai, Shuai
Zhong, Huang
Tai, Yang
Tong, Huan
Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials
title Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials
title_full Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials
title_fullStr Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials
title_full_unstemmed Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials
title_short Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials
title_sort gut microbiota therapy for nonalcoholic fatty liver disease: evidence from randomized clinical trials
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884806/
https://www.ncbi.nlm.nih.gov/pubmed/36726574
http://dx.doi.org/10.3389/fmicb.2022.1004911
work_keys_str_mv AT hantingrui gutmicrobiotatherapyfornonalcoholicfattyliverdiseaseevidencefromrandomizedclinicaltrials
AT yangwenjuan gutmicrobiotatherapyfornonalcoholicfattyliverdiseaseevidencefromrandomizedclinicaltrials
AT tanqinghua gutmicrobiotatherapyfornonalcoholicfattyliverdiseaseevidencefromrandomizedclinicaltrials
AT baishuai gutmicrobiotatherapyfornonalcoholicfattyliverdiseaseevidencefromrandomizedclinicaltrials
AT zhonghuang gutmicrobiotatherapyfornonalcoholicfattyliverdiseaseevidencefromrandomizedclinicaltrials
AT taiyang gutmicrobiotatherapyfornonalcoholicfattyliverdiseaseevidencefromrandomizedclinicaltrials
AT tonghuan gutmicrobiotatherapyfornonalcoholicfattyliverdiseaseevidencefromrandomizedclinicaltrials

Ejemplares similares